Bromocriptine in the Treatment of Galactorrhea Caused by Haloperidol

Shenoy, Ramakrishnan S.; Ettigi, Prakash; Johnson, Carl Hirschie

doi:10.1097/00004714-198306000-00010

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, Donald et al [5] reported that all patients exhibiting phenothi azine-induced hyperprolactinemia experienced a de crease in prolactin concentration following an oral 2.5-mg dose of bromocriptine. A recent case report by Shenoy et al [12] of a 34-year-old female suffering from chronic paranoid schizophrenia describes the use of bro mocriptine therapy in this patient to control galactorrhea and amenorrhea secondary to haloperidol-induced hy perprolactinemia. Combined use of bromocriptine and haloperidol proved effective in managing the patient's psychotic condition while treating her galactorrheaamenorrhea syndrome.…”

Section: Introductionmentioning

confidence: 99%

Effect of Bromocriptine Mesylate on Induced Hyperprolactinemia in Stabilized Psychiatric Outpatients Undergoing Neuroleptic Treatment

Cohn

Brust²,

Diserio³

et al. 1985

Neuropsychobiology

View full text Add to dashboard Cite

Therapeutic doses of phenothiazines increased serum levels of prolactin, resulting in a number of side effects. Bromocriptine, a potent dopamine agonist, appears to effectively reduce the serum prolactin level. In this open pilot study, bromocriptine mesylate (Parlodel, Sandoz) was administered in an escalating dose schedule to 11 stabilized psychiatric outpatients with hyperprolactinemia resulting from thioridazine HC1 (Mellaril, Sandoz) treatment. 6 of 9 patients showed decreases. Overall global psychiatric evaluations were unchanged over the course of combined therapy for all but 1 patient, who showed improvement. The trend of decreased prolactin serum levels indicates that bromocriptine mesylate may prove a useful adjunct to reduce the side effects of hyperprolactinemia.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Bromocriptine Mesylate on Induced Hyperprolactinemia in Stabilized Psychiatric Outpatients Undergoing Neuroleptic Treatment

Cohn

Brust²,

Diserio³

et al. 1985

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…Amenorrhea and galactorrhea have often been observed in female patients under chronic neuroleptic treatment? 29 Neuroleptics induce an elevation in the plasma prolactin level, which is assumed to be one etiology of luteal insufficiency.5 I@ 2r, The relationship between male sexual dysfunctions and hyperprolactinemia has also been discussed. In men, hyperprolactinemia has been reported to induce impotence and a loss of 1ibido.l 33 These hormonal side effects have Received for publication April 3, 1986.…”

Section: Introductionmentioning

confidence: 99%

Effects of Bromocriptine on Neuroleptic‐Induced Amenorrhea, Galactorrhea and Impotence

Matsuoka

Nakai

Miyake

et al. 1986

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

The effects of bromocriptine on neuroleptic‐induced endocrinological disturbances (amenorrhea, galactorrhea and impotence) were investigated. Bromocriptine (5.0‐7.5 mg/day) was administered to psychiatric patients receiving neuroleptics and developing hyperprolactinemia. The following results were obtained. 1. Menses recurred in 7 of 10 patients with amenorrhea. 2. A decrease in lactation appeared in 5 of 6 patients with galactorrhea. 3. A significant increase in the serum levels of testosterone was observed after 8 weeks of the treatment in male patients. (N = 6) 4. There was no remarkable deterioration in regard to the psychotic symptoms in schizophrenic patients. (N = 7) 5. In non‐schizophrenic patients (N = 9), a significant improvement was observed in regard to “somatic concern” (in Brief Psychiatric Rating Scale).

show abstract

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

Tollin

2000

J Endocrinol Invest

View full text Add to dashboard Cite

Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors. In several reports, clinically significant hyperprolactinemia has been reported in patients on this agent. However, the optimal management of risperidone-induced hyperprolactinemia has not been clarified. We reviewed the records of 5 patients with psychotic disorders who were evaluated for risperidone-induced hyperprolactinemia. There were 4 females and 1 male patient, aged 30-45 yr. All patients had significant hyperprolactinemia, with prolactin (PRL) levels ranging from 65.5 to 209 microg/l. All but 1 of these patients had manifestations of hypogonadism. In these 4 patients, risperidone therapy was continued and the dopamine agonists bromocriptine or cabergoline were added. In 3 out of 4 patients, such additional therapy reduced the PRL level and alleviated hypogonadism. None of the patients treated with these agents had a worsening of psychosis. We conclude that risperidone can cause clinically significant hyperprolactinemia in patients treated with this drug. If risperidone therapy must be continued in such patients, addition of the dopamine agonists bromocriptine or cabergoline may successfully alleviate hyperprolactinemia and the associated manifestations without worsening psychotic symptoms.

show abstract

Bromocriptine in the Treatment of Galactorrhea Caused by Haloperidol

Cited by 8 publications

References 0 publications

Effect of Bromocriptine Mesylate on Induced Hyperprolactinemia in Stabilized Psychiatric Outpatients Undergoing Neuroleptic Treatment

Effect of Bromocriptine Mesylate on Induced Hyperprolactinemia in Stabilized Psychiatric Outpatients Undergoing Neuroleptic Treatment

Effects of Bromocriptine on Neuroleptic‐Induced Amenorrhea, Galactorrhea and Impotence

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

Contact Info

Product

Resources

About